この問題で

DIGITAL RESET
Nothing could have prepared the world for the unprecedented chain of events over the past two years. We prefaced 2020 and 2021 saying anything is possible, but no one saw this level of hyper volatility completely disrupting business and life as we know it. While the world is now firmly planted in a digital-format, the economic and business outlook for 2022 will remain highly fluid owing to the pandemic. Moreover, it is indeed very likely that in 2022, the majority of Asia Pacific’s GDP will be coming from digital products, services, and experiences across industries, with life scien

Korea issues marketing authorisation to Moderna COVID-19 vaccine

American firm Moderna has announced that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorisation for Spikevax, Moderna's COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.

1 min

Gilead Sciences to help end HIV epidemic in APAC with $1.5 M grant

US-based Gilead Sciences has announced the recipients of its 2021 Gilead Asia Pacific (APAC) Rainbow Grant, a regional grant programme that supports community-led projects which place people living with HIV and their communities at the heart of care.

1 min

CEPI funds project to develop COVID-19 vaccines for variants

Norway-based CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. in the US have announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other beta coronaviruses.

1 min

DIGITAL RESET

Nothing could have prepared the world for the unprecedented chain of events over the past two years. We prefaced 2020 and 2021 saying anything is possible, but no one saw this level of hyper volatility completely disrupting business and life as we know it. While the world is now firmly planted in a digital-format, the economic and business outlook for 2022 will remain highly fluid owing to the pandemic. Moreover, it is indeed very likely that in 2022, the majority of Asia Pacific's GDP will be coming from digital products, services, and experiences across industries, with life sciences being one of them.

10+ mins

Are Boosters Another Shot In The Dark?

Omicron and newer emerging variants have been portrayed as a cause of concern globally as several low and middle-income countries have not been able to immunise their citizens due to the shortage of COVID-19 vaccines. Notably, it was in the double-vaccinated South African individuals that the Omicron variant was first discovered. The COVID-19 Vaccines Global Access (COVAX) had promised two billion doses of COVID-19 vaccines by the end of 2021 to a total of 92 low-and middle-income countries that are eligible to receive COVID-19 vaccines through the COVAX mechanism. But, it has managed to deliver only about 95 million doses as developed nations hoarded surplus doses of the vaccines. Approximately 75 per cent of the 4.5 billion first doses of the COVID-19 vaccine that were rolled out, went to affluent countries. Can emerging variants make vaccine inequity a bigger challenge than it already is? Let's unravel.

5 mins

Can Supply Chains Turn Pandemic-Proof?

The sudden and extreme impact on supplier/distributor network in light of the pandemic, forced policymakers and pharma companies to rethink about supply chains. Has the industry rose to the challenge and mitigated those issues while also ensuring the supply chain remains resilient to future disruptions? Let's find out.

7 mins

Seeking The 'Fountain Of Youth'

In September 2021, Amazon founder Jeff Bezos invested in longevity biotech startup, Altos Labs putting the spotlight on the field of anti-ageing. Pharma and biotech firms are investing in research that could prevent and reverse the ageing process in humans, but can novel therapies actually provide longevity? Let's find out.

7 mins

We want to work with global innovation leaders in disruptive technologies

A company's agile structure depends on creating a network of scientific advisors and venture partners to accelerate its innovations and potentials. To achieve this, venture capitalists assist healthcare and biopharmaceutical companies at all stages of development, be it company's early-stage designing, stimulating transformative technologies or nurturing business growth. Erning Cao, Investment Director at Evonik Venture Capital (Shanghai, China) shares insights on strategic venture capital investment towards innovative business models in APAC healthcare industry promoting sustainable and ethical practices in the region.

5 mins

2022 seeks holistic revamping of pharma regulations

With the increasing relevance of the pharmaceutical industry, worldwide, as well as domestically, developments in regulation and policy pertaining to the industry are being keenly watched. We explore the expectations of a few opportunities and challenges that are projected for this industry in the coming year.

5 mins

Hong Kong Studies Impact Of Pfizer Vaccine On Omicron Variant

A recent study jointly conducted by the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and the Faculty of Medicine, The Chinese University of Hong Kong (CU Medicine) has revealed that Omicron, the latest COVID-19 variant, can significantly reduce the virus neutralisation ability of Pfizer BioNTech (BNT162b2) vaccine by 32 folds or more. A similar test of another vaccine used in Hong Kong, CoronaVac, is being conducted and the results will soon be available.

1 min

BioSpectrum Asia の記事をすべて読む

BioSpectrum Asia Magazine Description:

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.